Access the full text.
Sign up today, get DeepDyve free for 14 days.
S. Ward, E. Kaltenthaler, J. Cowan, M. Marples, B. Orr, M. Seymour (2006)
The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancerBritish Journal of Cancer, 95
Toshiaki Watanabe, M. Itabashi, Y. Shimada, Shinji Tanaka, Yoshinori Ito, Y. Ajioka, T. Hamaguchi, I. Hyodo, M. Igarashi, H. Ishida, M. Ishiguro, Y. Kanemitsu, N. Kokudo, K. Muro, A. Ochiai, M. Oguchi, Y. Ohkura, Yutaka Saito, Y. Sakai, H. Ueno, T. Yoshino, T. Fujimori, N. Koinuma, T. Morita, G. Nishimura, Y. Sakata, Keiichi Takahashi, H. Takiuchi, O. Tsuruta, Toshiharu Yamaguchi, Masahiro Yoshida, Naohiko Yamaguchi, K. Kotake, K. Sugihara, Japanese Rectum (2011)
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancerInternational Journal of Clinical Oncology, 17
Katsuki Ito, H. Nakazato, A. Koike, H. Takagi, S. Saji, S. Baba, M. Mai, J. Sakamoto, Y. Ohashi (2004)
Long-term effect of 5-fluorouracil enhanced by intermittent administration of polysaccharide K after curative resection of colon cancer. A randomized controlled trial for 7-year follow-up.International journal of colorectal disease, 19 2
M. Torisu, Y. Hayashi, T. Ishimitsu, T. Fujimura, K. Iwasaki, M. Katano, Hiroshi Yamamoto, Y. Kimura, M. Takesue, M. Kondo, K. Nomoto (1990)
Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancerCancer Immunology, Immunotherapy, 31
Eva Jiménez-Medina, Enrique Berruguilla, Irene Romero, I. Algarra, A. Collado, F. Garrido, Angel Garcia-Lora (2008)
The immunomodulator PSK induces in vitro cytotoxic activity in tumour cell lines via arrest of cell cycle and induction of apoptosisBMC Cancer, 8
Y. Honma, Y. Yamada, T. Terazawa, A. Takashima, S. Iwasa, Ken Kato, T. Hamaguchi, Y. Shimada, M. Ohashi, S. Morita, T. Fukagawa, N. Machida, H. Katai (2016)
Feasibility of neoadjuvant S-1 and oxaliplatin followed by surgery for resectable advanced gastric adenocarcinomaSurgery Today, 46
M. Okuzawa, H. Shinohara, Toshihiro Kobayashi, M. Iwamoto, M. Toyoda, N. Tanigawa (2002)
PSK, a protein-bound polysaccharide, overcomes defective maturation of dendritic cells exposed to tumor-derived factors in vitro.International journal of oncology, 20 6
B. Lembersky, H. Wieand, N. Petrelli, M. O’connell, L. Colangelo, Roy Smith, T. Seay, J. Giguere, M. Marshall, A. Jacobs, L. Colman, A. Soran, G. Yothers, N. Wolmark (2006)
Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 13
Hailing Lu, Yi Yang, E. Gad, C. Wenner, Amy Chang, Emily Larson, Y. Dang, M. Martzen, L. Standish, M. Disis (2010)
Polysaccharide Krestin Is a Novel TLR2 Agonist that Mediates Inhibition of Tumor Growth via Stimulation of CD8 T Cells and NK CellsClinical Cancer Research, 17
S. Ohwada, Toshirou Ikeya, T. Yokomori, T. Kusaba, T. Roppongi, Tooru Takahashi, Seiji Nakamura, S. Kakinuma, S. Iwazaki, H. Ishikawa, S. Kawate, Takashi Nakajima, Y. Morishita (2004)
Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled studyBritish Journal of Cancer, 90
Hugh Colvin, T. Mizushima, H. Eguchi, S. Takiguchi, Y. Doki, M. Mori (2017)
Gastroenterological surgery in Japan: The past, the present and the futureAnnals of Gastroenterological Surgery, 1
J. Sakamoto, J. Sakamoto, C. Hamada, C. Hamada, S. Yoshida, S. Yoshida, S. Kodaira, S. Kodaira, M. Yasutomi, M. Yasutomi, T. Kato, T. Kato, K. Oba, K. Oba, H. Nakazato, H. Nakazato, S. Saji, S. Saji, Y. Ohashi, Y. Ohashi (2007)
An individual patient data meta-analysis of adjuvant therapy with uracil–tegafur (UFT) in patients with curatively resected rectal cancerBritish Journal of Cancer, 96
Y. Shimada, T. Hamaguchi, J. Mizusawa, N. Saitō, Y. Kanemitsu, N. Takiguchi, M. Ohue, Takeshi Kato, Y. Takii, Toshihiko Sato, N. Tomita, S. Yamaguchi, M. Akaike, H. Mishima, Y. Kubo, Kenichi Nakamura, H. Fukuda, Y. Moriya (2014)
Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2/D3 lymph node dissection: final results of JCOG0205.European journal of cancer, 50 13
Y. Kodera (2017)
Neoadjuvant chemotherapy for gastric adenocarcinoma in JapanSurgery Today, 47
Conor Farrington, Godfrey Manning (1990)
Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk.Statistics in medicine, 9 12
T. Hamaguchi, K. Shirao, Y. Moriya, S. Yoshida, S. Kodaira, Y. Ohashi, The Group (2011)
Final results of randomized trials by the National Surgical Adjuvant Study of Colorectal Cancer (NSAS-CC)Cancer Chemotherapy and Pharmacology, 67
S. Topalian, F. Hodi, J. Brahmer, S. Gettinger, David Smith, David McDermott, J. Powderly, Richard Carvajal, J. Sosman, M. Atkins, P. Leming, D. Spigel, S. Antonia, L. Horn, Charles Drake, D. Pardoll, Lieping Chen, W. Sharfman, Robert Anders, J. Taube, T. McMiller, Haiying Xu, A. Korman, M. Jure-Kunkel, S. Agrawal, D. McDonald, G. Kollia, A. Gupta, J. Wigginton, M. Sznol (2012)
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.The New England journal of medicine, 366 26
M. Fisher, Li-xi Yang (2002)
Anticancer effects and mechanisms of polysaccharide-K (PSK): implications of cancer immunotherapy.Anticancer research, 22 3
S. Ohwada, M. Kawate (2003)
Adjuvant Therapy With Protein-Bound Polysaccharide K and Tegafur Uracil in Patients With Stage II or III Colorectal Cancer: Randomized, Controlled TrialDiseases of the Colon & Rectum, 46
H. Mieno, K. Yamashita, K. Hosoda, H. Moriya, K. Higuchi, M. Azuma, Shouko Komori, Tsutomu Yoshida, S. Tanabe, W. Koizumi, N. Katada, M. Watanabe (2017)
Conversion surgery after combination chemotherapy of docetaxel, cisplatin and S-1 (DCS) for far-advanced gastric cancerSurgery Today, 47
S. Sadahiro, Toshiyuki Suzuki, Y. Maeda, A. Tanaka, A. Kamijo, C. Murayama, Y. Nakayama, T. Akiba (2010)
Effects of preoperative immunochemoradiotherapy and chemoradiotherapy on immune responses in patients with rectal adenocarcinoma.Anticancer research, 30 3
N. Hirahara, M. Fujioka, T. Edamatsu, Ayako Fujieda, Fujio Sekine, T. Wada, Tsuneo Tanaka (2011)
Protein-bound polysaccharide-K (PSK) induces apoptosis and inhibits proliferation of promyelomonocytic leukemia HL-60 cells.Anticancer research, 31 9
Naohito Beppu, Hidenori Yoshie, F. Kimura, T. Aihara, H. Doi, N. Kamikonya, N. Matsubara, N. Tomita, H. Yanagi, N. Yamanaka (2016)
The short-term outcomes of induction SOX (S-1 + oxaliplatin) ± cetuximab chemotherapy followed by short-course chemoradiotherapy in patients with poor-risk locally advanced rectal cancerSurgery Today, 46
J. Kuebler, H. Wieand, M. O’connell, Roy Smith, L. Colangelo, G. Yothers, N. Petrelli, M. Findlay, T. Seay, J. Atkins, J. Zapas, J. Goodwin, L. Fehrenbacher, R. Ramanathan, B. Conley, P. Flynn, G. Soori, L. Colman, E. Levine, K. Lanier, N. Wolmark (2007)
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 16
E. Mitry (1990)
Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma.The New England journal of medicine, 323 3
Y. Ono, T. Hayashida, A. Konagai, H. Okazaki, Kazuhiro Miyao, S. Kawachi, M. Tanabe, M. Shinoda, H. Jinno, H. Hasegawa, M. Kitajima, Y. Kitagawa (2012)
Direct inhibition of the transforming growth factor‐β pathway by protein‐bound polysaccharide through inactivation of Smad2 signalingCancer Science, 103
Y. Maehara, S. Moriguchi, Y. Sakaguchi, Y. Emi, S. Kohnoe, S. Tsujitani, K. Sugimachi (1990)
Adjuvant chemotherapy enhances long‐term survival of patients with advanced gastric cancer following curative resectionJournal of Surgical Oncology, 45
M. Ooshiro, Yui Sugishita, Hiroshi Tanaka, Kazuki Koide, M. Nagashima, R. Katoh (2004)
Regulation of perioperative immunological changes following laparotomy: effects of biological response modifier (BRM) on surgical stress.Immunology letters, 93 1
M. Niimoto, T. Hattori, R. Tamada, K. Sugimachi, K. Inokuchi, N. Ogawa (1988)
Postoperative adjuvant immunochemotherapy with mitomycin C, futraful and PSK for gastric cancer. An analysis of data on 579 patients followed for five yearsThe Japanese journal of surgery, 18
T. André, C. Boni, L. Mounedji-Boudiaf, M. Navarro, J. Tabernero, T. Hickish, C. Topham, M. Zaninelli, P. Clingan, J. Bridgewater, I. Tabah-Fisch, A. Gramont (2004)
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.The New England journal of medicine, 350 23
D. Haller, J. Tabernero, J. Maroun, F. Braud, T. Price, E. Cutsem, M. Hill, F. Gilberg, K. Rittweger, H. Schmoll (2011)
Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 11
Surg Today (2018) 48:66–72 https://doi.org/10.1007/s00595-017-1555-1 ORIGINAL ARTICLE Phase III trial comparing UFT + PSK to UFT + LV in stage IIB, III colorectal cancer (MCSGO‑CCTG) 1 2 3 4 5 2 Yasuhiro Miyake · Junichi Nishimura · Takeshi Kato · Masataka Ikeda · Masaki Tsujie · Taishi Hata · 2 2 2 4 1 Ichiro Takemasa · Tsunekazu Mizushima · Hirofumi Yamamoto · Mitsugu Sekimoto · Riichiro Nezu · 2 2 Yuichiro Doki · Masaki Mori · Multi‑ center Clinical Study Group of Osaka, Colorectal Cancer Treatment Group (MCSGO) Received: 21 December 2016 / Accepted: 22 May 2017 / Published online: 20 June 2017 © Springer Japan KK 2017 Abstract or UFT/LV (n = 179) (median age 65 years, colon/ Purpose Oral adjuvant uracil and tegafur plus leucovorin rectum 67.4/32.6%, stage IIB/IIIA/IIIB/IIIC (UFT/LV) is not inferior to standard weekly fluorouracil 11.1/15.7/55.0/18.2%). The 3-year DFS rate was 82.3% and folinate for stage II/III colon cancer. However, protein- in those receiving UFT/LV and 72.1% in those receiv- bound polysaccharide K (PSK) has been evaluated as post- ing UFT/PSK. The non-inferiority of UFT/PSK adjuvant operative adjuvant therapy for colorectal cancer. This report therapy to UFT/LV therapy was not verified ( −9.06%, 90%
Surgery Today – Springer Journals
Published: Jun 20, 2017
Access the full text.
Sign up today, get DeepDyve free for 14 days.